SEC Tracker
Get the app

Aimmune Therapeutics

Aimmune Therapeutics: ends a material agreement, completes an acquisition or sale of assets and 6 other items

Form
8-K
Filed
Importance
Routine
  • Ends a material agreement (1.02)
  • Completes an acquisition or sale of assets (2.01)
  • Says a debt obligation was accelerated (2.04)
  • Reports an exchange listing deficiency notice (3.01)
  • Changes shareholder rights (3.03)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Aimmune Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.